Did Canopy Growth beat or miss consensus estimates last quarter?

What were the key takeaways from Canopy Growth’s earnings call?

What is the revenue and EPS growth rate for Canopy Growth year over year?

What is Canopy Growth's gross profit margin?

What were the key takeaways from Canopy Growth's earnings call?

What is Canopy Growth's latest dividend and current dividend yield?

What guidance did Canopy Growth's management provide for the next earnings period?

What is the market's earnings forecast for Canopy Growth next quarter?

- **Record Financial Health**: CAD 371M cash and net cash position of CAD 146M, with debt extended to 2031, enabling strategic flexibility.
- **MTL Acquisition**: Expected to enhance Canadian medical leadership and fuel international growth, with accretive EBITDA contributions.
- **Canadian Growth Momentum**: Medical cannabis revenue up 15% YoY, adult use up 8% YoY, driven by innovation and operational excellence.
- **Cost Efficiency**: $29M annualized savings, narrowing Adjusted EBITDA loss to CAD 3M, with FY2027 positive EBITDA target.
- **European Expansion**: Flower supply improvements and EU GMP certification position Canopy for European medical market growth.

**【CEO Summary Section】**
- **Financial Strength**: Ended Q3 with CAD 371M in cash and a net cash position of CAD 146M. Post-quarter recapitalization extended debt maturities to 2031, enhancing liquidity and flexibility.
- **MTL Acquisition**: Proposed acquisition of MTL Cannabis to strengthen Canadian medical and adult use, with high-quality flower supply for international markets. Expected to be accretive to Adjusted EBITDA.
- **Canadian Growth**: Canadian medical cannabis revenue up 15% YoY, adult use up 8% YoY, driven by innovation in pre-rolls and vapes. Focus on elevating flower quality and expanding into Europe.
- **International Momentum**: International cannabis sales grew 22% sequentially, with stabilization and operational improvements. Storz & Bickel revenue increased 45% sequentially, driven by new VZ vaporizer sales.

**【CFO Financial Commentary】**
- **Adjusted EBITDA**: Narrowest loss to date at CAD 3M, with $29M annualized cost savings exceeding expectations. Targeting positive Adjusted EBITDA in FY2027.
- **Segment Performance**: 
  - **Global Cannabis**: Net revenue $52M (4% YoY), with Canada Medical up 15% and Canada Adult Use up 8%. International sales grew 22% sequentially.
  - **Gross Margins**: Cannabis gross margin 25% (down 3pp YoY due to international mix). Storz & Bickel gross margin 37% (down 3pp YoY due to tariffs).
  - **Operating Expenses**: SG&A down 12% YoY, reflecting cost discipline.
  - **Free Cash Flow**: Outflow of CAD 19M (improvement vs. prior year). Expecting sequential improvements in Q4 and FY2027.
- **MTL Impact**: Post-closing, MTL’s results will be consolidated, contributing to revenue, gross margin, and EBITDA improvements.

**【Q&A Highlights】**
- **International Growth**: Europe-focused expansion with improved flower supply and EU GMP certification at Smiths Falls. Q3 European sales team had 2 strains; Q1 2027 to offer over 12 strains.
- **Gross Margin Outlook**: Targeting mid-30s blended gross margin post-MTL, driven by European high-price medical markets.
- **EBITDA Expectations**: Positive Adjusted EBITDA achievable in FY2027, excluding MTL contributions. Cost-saving actions mitigate veteran reimbursement cap reduction impact.
- **Storz & Bickel Strategy**: Expanding into affordability (VZ device) and concentrates market to drive U.S. penetration.
- **Balance Sheet Flexibility**: Reduced ATM usage with strong cash position, preserving capacity for strategic opportunities.

Canopy Growth Corp (CGC) Q3 2026 Earnings Call Transcript

- **Canadian dominance**: 30% revenue growth in adult-use, 17% medical expansion, and 12% cannabis segment growth.
- **Cost efficiency**: CAD 21M+ savings vs. CAD 20M target, supporting 2026 EBITDA positivity.
- **International turnaround**: Europe restructuring to 100% Canadian-sourced flower, positioning for H2 profitability.


**【Management Opening Remarks】**
- Canopy Growth issued Q2 FY2026 financial results with CAD 51 million in cannabis net revenue, up 12% year-over-year. 
- The company achieved CAD 298 million in cash and cash equivalents, exceeding debt balances by CAD 70 million.
- Adjusted EBITDA loss narrowed significantly, driven by cost-saving initiatives and improved gross margins.

**【CEO Summary Section】**
- Canadian adult-use cannabis revenue grew 30% YoY, driven by Claybourne-infused pre-rolls and Tweed all-in-one vapes.
- Medical cannabis revenue increased 17% YoY, supported by patient registrations and product assortment expansion.
- International markets faced supply chain challenges, but Europe-focused restructuring is underway.

**【CFO Financial Commentary】**
- Q2 operating expenses declined 13% YoY, with CAD 21 million in annualized savings vs. CAD 20 million target.
- Free cash flow improved 67% YoY, reflecting debt reduction and working capital management.

**【Q&A Highlights】**
- Europe retooling to source 100% of flower from Canadian GMP facilities.
- Positive adjusted EBITDA expected in H2 FY2026 through cost management and capacity utilization.
- Storz & Bickel VZ Vaporizer sales up 5% QoQ, targeting holiday season growth.


Canopy Growth Corp (CGC) Q2 2026 Earnings Call Transcript

- **Revenue Growth**: Cannabis segment up 24% YoY, driven by Canada adult-use (43% YoY) and Germany's triple-digit expansion.
- **Cost Savings**: $17M annualized savings (85% of $20M target), with further efficiency initiatives to improve margins.
- **Storz & Bickel Turnaround**: New device launch expected to drive H2 recovery, with gross margin improvement through in-house manufacturing.
- **Cash Flow Improvement**: Free cash flow outflow reduced to $12M, debt down to $295M with interest savings of $6.5M annually.
- **U.S. Market Potential**: Canopy USA focusing on cost reduction and strategic market expansion, with Acreage securing $20M funding.

**【CEO Summary Section】**
- **Cannabis Segment Growth**: Q1 net revenue rose 24% YoY, driven by 13% growth in Canada Medical (outpacing the market) and 43% surge in Canada adult-use. Germany saw triple-digit growth, offsetting softness in Poland and Australia.
- **Cost Efficiency**: Achieved $17M in annualized savings (85% of $20M target), with further efficiency initiatives underway.
- **Margin Focus**: Gross margin improvement is a top priority, with actions like production automation and bulk cannabis sales to enhance profitability.
- **Storz & Bickel Update**: Q1 revenue down 25% YoY due to macroeconomic challenges, but new device launch expected to boost performance in H2.
- **U.S. Strategy**: Canopy USA focusing on cost reduction and strategic markets, with Acreage securing $20M funding post-restructuring.

**【CFO Financial Commentary】**
- **Top-Line Performance**: Cannabis segment revenue $57M (24% YoY), Storz & Bickel $15M (25% YoY decline). Canada adult-use and medical growth offset Storz & Bickel softness.
- **Gross Margin Challenges**: Cannabis gross margin 24% (down YoY) due to higher production costs for Claybourne pre-rolls and Poland supply issues. Storz & Bickel gross margin 29% (39% YoY decline).
- **Cost Control**: SG&A expenses down 21% YoY, driven by headcount reduction (15% YoY) and operational streamlining.
- **Cash Flow & Debt**: Free cash flow outflow $12M (vs. $56M YoY), debt reduced to $295M. Prepayments to reduce interest expense by $6.5M annually.
- **Future Outlook**: Targeting cannabis gross margin in low to mid-30s by year-end, with focus on Europe supply improvements and U.S. market expansion.

**【Q&A Highlights】**
- **Gross Margin Drivers**: Sequential improvement in cannabis margin due to production efficiency gains and supply optimization. New automation expected to reduce labor costs.
- **Poland Recovery**: Supply challenges resolved; process improvements to restore growth in Q2+.
- **European Expansion**: Germany and Poland key near-term focuses, with new product registrations and supply increases. Longer-term, monitoring regulatory reforms in other markets.
- **U.S. Momentum**: Despite no rescheduling, select states show infrastructure development and demand growth, positioning Canopy for future profitability.

Canopy Growth Corporation (CGC) Q1 2026 Earnings Call Transcript

- **$20M Cost Savings Target**: 50% executed, with $13M annual interest expense reduction from $100M debt prepayment.
- **Canada Medical Momentum**: 13% YoY growth, 25% cash gross margin, gaining market share via insurer focus.
- **Storz & Bickel Recovery**: New device launch Q4 2025; 2026 sales expected to improve post-macro stabilization.
- **Canopy USA Challenges**: Acreage underperforming in Ohio/New Jersey; U.S. fair value down 44% to $178M.


**【CEO Comprehensive Review】**
- **Organizational Restructuring**: Streamlined global medical cannabis operations into a single structure, focusing on Germany, Poland, and Australia to enhance market responsiveness and supply consistency. Canadian adult-use business now prioritizes high-margin formats like pre-rolls and vapes, with a 33% SKU rationalization.
- **Cost Optimization**: Targeting $20M annualized cost savings through headcount reduction, leaner sales/marketing, and operational efficiency. $100M early debt prepayment reduces annual interest expense by $13M.
- **Execution Excellence**: Improved fill rates from mid-80s to mid-90s via better forecasting and coordination. New product development gate process ensures margin-accretive launches (e.g., 3 & 7 Acres vapes).

**【CFO Financial Highlights】**
- **Q4 2025 Results**: Net revenue $137M (down 23% YoY), adjusted EBITDA loss $9M (improvement of $6M YoY). Free cash flow outflow $36M vs. $23M YoY, driven by higher CapEx and working capital.
- **Canada Medical Strength**: 13% YoY growth, 25% full-year cash gross margin. Focus on insurer patients and Spectrum online store expansion.
- **Global Challenges**: Storz & Bickel revenue down 23% YoY due to macroeconomic pressures; Poland medical sales down due to regulatory changes. Canopy USA faces liquidity challenges, with Acreage underperforming in Ohio and New Jersey.

**【Q&A Key Takeaways】**
- **Cost Savings Urgency**: 50% of $20M savings already executed; aiming for positive adjusted EBITDA in 2026.
- **Medical Growth Drivers**: Canada medical gaining market share (16% YoY vs. market decline). Global medical recovery in Poland expected as supply stabilizes.
- **Storz & Bickel Outlook**: New device launch Q4 2025 to drive second-half recovery; 50% DTC sales decline in Q1 2025 highlights macroeconomic headwinds.
- **Canopy USA Risks**: Acreage in default; Canopy USA fair value down 44% YoY to $178M, reflecting U.S. market challenges.


Canopy Growth Corporation (CGC) Q4 2025 Earnings Call Transcript

- **Medical Cannabis Dominance**: Poland up 70% YoY, Canada medical revenue +16% YoY. 
- **Adult Use Turnaround**: Claybourne pre-rolls rank #3 in Canada, Wana gummies relaunch driving recovery. 
- **Profitability Progress**: Adjusted EBITDA loss narrows to CAD3M (-61% YoY), free cash flow improves 17% YoY. 
- **US Expansion Ambition**: Canopy USA integration on track, targeting US market with Wana/Jetty/Acreage synergies. 
- **Liquidity Security**: CAD250M term loan reduced, CAD228M ATM proceeds provide growth flexibility. 


**【CEO Opening Remarks】**
- CEO Luc Mongeau emphasized a **new chapter of profitability and cash generation**, prioritizing medical cannabis growth and adult use innovation. 
- Highlighted **Claybourne pre-roll success** (ranked #3 in Canada within 6 weeks) and Storz & Bickel's premium vaporizer leadership. 
- **Canopy USA integration** is progressing with Brooks Jorgensen as President, targeting US market expansion through Wana, Jetty, and Acreage synergies.

**【CFO Financial Highlights】**
- Q3 2025 revenue: CAD75M (-5% YoY, +8% ex-divested businesses). 
- **Adjusted EBITDA loss narrowed to CAD3M** (-61% YoY), driven by medical cannabis growth and cost reductions. 
- **Free cash flow outflow improved to CAD28M** (-17% YoY). 
- Key metrics: 
  - Canada medical revenue +16% YoY, Poland market up 70% YoY. 
  - Storz & Bickel revenue +19% YoY to CAD22M. 
  - SG&A expenses down 24% YoY to CAD35M. 

**【Q&A Key Takeaways】**
1. **International Growth Strategy**: 
   - Poland: 70% YoY growth, supply constrained by import permits. 
   - Germany: Tweed flower launches, asset-light partnerships. 
   - Australia: Transitioning S&B sales to Germany to focus on medical cannabis. 
2. **Canopy USA Outlook**: 
   - Acreage integration completed, cost synergies materializing. 
   - Wana gummies relaunch driving adult use recovery. 
3. **Financial Discipline**: 
   - Term loan reduced to CAD250M, ATM program provides CAD228M liquidity. 
   - Target: Positive consolidated EBITDA in coming quarters. 
4. **Constellation Brands Role**: 
   - Passive investor with no direct US distribution collaboration. 
   - Focus on internal capabilities for US market entry. 


Actual							-26.1355	-2.2026	-0.6738	-19.0738	-14.7193	6.7835	-0.2365	-2.2137	-11.6683	-40.6094	-3.3962	-3.9836	-9.4643	-0.5281	-3.1652	-1.9768	-0.7603	-1.1691	-1.0938	-0.7713	-0.9936	-0.1616	-0.0072	-0.1314
Forecast							-4.1475	-3.079	-2.7575	-2.5445	-2.0024	-2.0907	-1.5843	-2.2532	-2.4485	-2.2207	-1.9479	-1.6311	-1.5347	-1.3328	-1.156	-0.3801	-0.327	-0.3334	-0.339	-0.3276	-0.3209	-0.1697	-0.1128	-0.0411
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-530.15%	+28.46%	+75.56%	-649.61%	-635.08%	+424.46%	+85.07%	+1.75%	-376.55%	-1728.68%	-74.35%	-144.23%	-516.69%	+60.38%	-173.81%	-420.07%	-132.51%	-250.66%	-222.65%	-135.44%	-209.63%	+4.77%	+93.62%	-219.71%

CGC

CGC fundamentals

CGC Q3 2026 Earnings

Earnings Call

You can ask Aime

CGC

CGC fundamentals

CGC Q3 2026 Earnings

Earnings Call

CGC Earnings Call Summary for Q3/202610:00 AM on Feb 6, 2026

CGC Earnings Call Summary for Q2/202610:00 AM on Nov 7, 2025

CGC Earnings Call Summary for Q1/202610:00 AM on Aug 8, 2025

CGC Earnings Call Summary for Q4/202510:00 AM on May 30, 2025

CGC Earnings Call Summary for Q3/202510:00 AM on Feb 7, 2025

You can ask Aime